Translate
Obi Pharma, Inc.
About
32.40TWD+0.05 +0.15%
Live at 16:21 GMT+00:00Market Cap$134.41M
Volume256.0K
Beta-0.14
RSI36.09
Gross Margin-621.70%
Obi Pharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 12 2026
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Sep 2 2025
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
Jun 6 2025
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
May 1 2025
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC